Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A403XM | ISIN: US09057N4097 | Ticker-Symbol: IBP0
Berlin
22.02.24 | 21:52
0,340 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIO-PATH HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
BIO-PATH HOLDINGS INC 5-Tage-Chart

Aktuelle News zur BIO-PATH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBio-Path Holdings, Inc.: Bio-Path Holdings Provides Clinical and Operational Update85HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
► Artikel lesen
15.05.BIO-PATH HOLDINGS, INC. - 10-Q, Quarterly Report1
01.05.Bio-Path Holdings, Inc.: Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients61HOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
► Artikel lesen
29.04.BIO-PATH HOLDINGS, INC. - 8-K, Current Report1
28.03.BIO-PATH HOLDINGS, INC. - 8-K, Current Report1
28.03.Bio-Path GAAP EPS of -$4.122
28.03.Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Full Year 2024 Financial Results134HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
► Artikel lesen
BIO-PATH Aktie jetzt für 0€ handeln
27.03.BIO-PATH HOLDINGS, INC. - 10-K, Annual Report2
19.03.BIO-PATH HOLDINGS, INC. - 8-K, Current Report-
18.03.Bio-Path Holdings, Inc.: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients95HOUSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
► Artikel lesen
07.03.BIO-PATH HOLDINGS, INC. - 8-K, Current Report-
27.02.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.02.20253.087The following instruments on Boerse Frankfurt do have their last trading day on 27.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.02.2025ISIN NameCA15748D1069 CHAKANA...
► Artikel lesen
18.02.BIO-PATH HOLDINGS, INC. - 8-K, Current Report9
13.02.Bio-Path Holdings, Inc.: Bio-Path Holdings Expands Global Patent Portfolio130HOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
► Artikel lesen
13.02.Bio-Path Holdings, Inc.: Bio-Path Holdings Provides Key Clinical Updates172First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase...
► Artikel lesen
12.02.Bio-Path Holdings, Inc.: Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia109Study Progresses to Fourth Higher 90 mg/m2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12...
► Artikel lesen
12.02.BIO-PATH HOLDINGS, INC. - S-1/A, General form for registration of securities-
21.01.BIO-PATH HOLDINGS, INC. - S-1, General form for registration of securities-
10.01.BIO-PATH HOLDINGS, INC. - 8-K, Current Report-
10.01.Bio-Path bereitet sich auf wichtige klinische Meilensteine im Jahr 2025 vor1
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1